Chemicals · Founded 2005 · www.srhhl.com · BSE 532842 · NSE SREE RAYALA · ISIN INE917H01012
No Notes Added Yet
Business
Sree Rayalaseema Hi-Strength Hypo Ltd. (SRHHYPOLTD) is an Indian chemical manufacturing company primarily engaged in the production and sale of Calcium Hypochlorite. Calcium Hypochlorite, commonly known as bleaching powder, is a key chemical used as a disinfectant, oxidizing agent, and bleaching agent. The company's core business model involves manufacturing this bulk chemical and supplying it to various end-user industries. It makes money by selling its manufactured calcium hypochlorite to customers for applications such as water treatment, sanitation, textile bleaching, paper manufacturing, and various other industrial processes.
Revenue Mix
The company's primary business segment revolves around the manufacture and sale of Calcium Hypochlorite. While the product itself is singular, its applications span multiple industries. Revenue is derived almost entirely from the sales of this chemical, with variations likely stemming from different grades or packaging sold to diverse customer segments (e.g., municipal water boards, industrial users, agricultural applications). Detailed segment-wise revenue contribution beyond this core product is typically not disclosed for such a focused manufacturer.
Industry
SRHHYPOLTD operates within the broader Chemicals sector, specifically in the manufacture of a bulk inorganic chemical, Calcium Hypochlorite. The industry is characterized by being commodity-driven, implying price sensitivity and competition based on cost efficiency, product quality, and distribution reach. In India, the market for calcium hypochlorite includes a few large players and several smaller regional manufacturers. SRHHYPOLTD has an established presence, being one of the more recognized manufacturers of this specific chemical in the country, leveraging its operational history and capacity. Its positioning is likely as a mid-tier player with a strong regional footprint and established customer base.
MOAT
For a bulk chemical manufacturer like SRHHYPOLTD, traditional moats often relate to:
Cost Leadership: Through economies of scale, efficient manufacturing processes, and potentially favorable access to raw materials or energy, allowing them to produce at a lower cost than competitors.
Established Customer Relationships & Distribution Network: A long operational history can translate into strong, sticky customer relationships and a robust supply chain that is difficult for new entrants to replicate quickly.
Regulatory Compliance & Expertise: Navigating the complex environmental and safety regulations for chemical manufacturing can be a barrier to entry, which an incumbent like SRHHYPOLTD has already mastered.
However, being a commodity product, it faces challenges in building a strong brand moat or high switching costs directly attributable to the product itself, making cost efficiency and reliability paramount.
Growth Drivers
Key factors that could drive SRHHYPOLTD's growth over the next 3-5 years include:
Increasing Demand for Water Treatment & Sanitation: Government initiatives like the Swachh Bharat Abhiyan and rising awareness about hygiene will drive demand for disinfectants and water purification chemicals.
Industrial Growth: Expansion in end-user industries such as textiles, paper, and aquaculture will naturally increase the consumption of calcium hypochlorite.
Urbanization and Infrastructure Development: Growing cities and new infrastructure projects will require more effective water and wastewater treatment, boosting demand.
Exports: Potential to expand into international markets, especially in developing economies with growing industrial and sanitation needs.
Capacity Expansion/Modernization: Investing in increasing production capacity or improving efficiency could lead to higher sales volumes and better margins.
Risks
Raw Material Price Volatility: The production of calcium hypochlorite relies on inputs like chlorine, lime, and energy (coal/power). Fluctuations in the prices of these raw materials can significantly impact profitability.
Intense Competition & Price Pressure: Being a commodity chemical, the market is competitive, and the company can face pressure on selling prices, especially during periods of oversupply or economic slowdown.
Environmental & Regulatory Risks: Chemical manufacturing is subject to stringent environmental regulations. Changes in these regulations or non-compliance can lead to increased operational costs, fines, or operational disruptions.
Demand Cyclicality: Demand from industrial customers can be cyclical, tied to broader economic health, impacting sales volumes.
Technological Obsolescence/Substitution: While calcium hypochlorite is a fundamental chemical, the emergence of newer, more efficient, or cheaper alternative disinfectants/bleaching agents could pose a long-term risk.
Management & Ownership
Sree Rayalaseema Hi-Strength Hypo Ltd. is primarily promoter-owned and managed, a common structure among Indian companies. The promoter group, with a significant equity stake (typically around 60-70%), retains control and strategic direction. The management team likely comprises individuals with experience in the chemicals industry, particularly in manufacturing and operations. The quality of management is reflected in the company's long operational history and its ability to navigate the cyclical nature of the chemical industry.
Outlook
SRHHYPOLTD operates in a foundational segment of the chemical industry, benefiting from consistent demand for water treatment, sanitation, and industrial applications. The company's long-standing presence and established manufacturing capabilities provide a stable base.
The bull case centers on India's growth story, particularly increasing urbanization, industrialization, and a strong government focus on hygiene and water infrastructure, which directly drives demand for the company's core product. Efficient cost management and potential capacity expansions could further enhance profitability.
Conversely, the bear case highlights the challenges of operating in a commodity business. Volatile raw material prices, intense competition leading to pricing pressures, and the ever-present risk of stringent environmental regulations could compress margins and limit growth. The lack of significant product diversification also concentrates risk.
Overall, SRHHYPOLTD appears to be a stable, niche player in the Indian chemical sector with exposure to essential services, but its financial performance will remain sensitive to commodity cycles and operational efficiencies.
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 165 | 169 | 170 | 138 | 160 | 180 | 182 | 141 | 163 | 211 |
| Other Income | 9 | 2 | 9 | 13 | 15 | 10 | 7 | 19 | 18 | 10 |
| Total Income | 174 | 171 | 179 | 151 | 176 | 191 | 189 | 161 | 181 | 221 |
| Total Expenditure | 138 | 143 | 141 | 119 | 143 | 152 | 155 | 121 | 150 | 181 |
| Operating Profit | 36 | 28 | 38 | 32 | 33 | 38 | 34 | 40 | 31 | 40 |
| Interest | 2 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Depreciation | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Exceptional Income / Expenses | -5 | 0 | 0 | 0 | -3 | -5 | 0 | -3 | -6 | -4 |
| Profit Before Tax | 26 | 26 | 36 | 30 | 27 | 31 | 32 | 34 | 23 | 34 |
| Provision for Tax | 6 | 7 | 11 | 9 | 5 | 9 | 9 | 10 | 3 | 9 |
| Profit After Tax | 20 | 19 | 25 | 22 | 22 | 22 | 23 | 24 | 20 | 25 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | 0 |
| Profit After Adjustments | 20 | 19 | 25 | 22 | 22 | 23 | 23 | 24 | 20 | 25 |
| Adjusted Earnings Per Share | 11.4 | 10.8 | 14.7 | 12.6 | 12.8 | 13.3 | 13.6 | 13.8 | 11.7 | 14.5 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 363 | 164 | 689 | 911 | 1267 | 1650 | 866 | 638 | 667 | 697 |
| Other Income | 4 | 0 | 4 | 7 | 11 | 35 | 22 | 40 | 55 | 54 |
| Total Income | 367 | 165 | 693 | 917 | 1278 | 1685 | 888 | 678 | 722 | 752 |
| Total Expenditure | 319 | 142 | 587 | 781 | 1119 | 1470 | 755 | 546 | 578 | 607 |
| Operating Profit | 48 | 22 | 106 | 137 | 159 | 215 | 133 | 132 | 143 | 145 |
| Interest | 11 | 3 | 10 | 5 | 3 | 5 | 4 | 2 | 2 | 1 |
| Depreciation | 10 | 10 | 50 | 51 | 19 | 19 | 11 | 7 | 7 | 8 |
| Exceptional Income / Expenses | -1 | 0 | 0 | 0 | 0 | 0 | -11 | -3 | -14 | -13 |
| Profit Before Tax | 25 | 9 | 45 | 81 | 137 | 190 | 107 | 119 | 121 | 123 |
| Provision for Tax | 7 | -0 | 8 | 20 | 34 | 36 | 28 | 32 | 31 | 31 |
| Profit After Tax | 19 | 9 | 38 | 61 | 103 | 154 | 79 | 87 | 90 | 92 |
| Adjustments | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 0 |
| Profit After Adjustments | 25 | 9 | 38 | 61 | 103 | 154 | 79 | 90 | 91 | 92 |
| Adjusted Earnings Per Share | 17 | 5.9 | 22.1 | 35.3 | 59.9 | 89.9 | 46.1 | 52.5 | 53.2 | 53.6 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 5% | -26% | -6% | 0% |
| Operating Profit CAGR | 8% | -13% | 1% | 0% |
| PAT CAGR | 3% | -16% | 8% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -12% | -5% | 8% | 14% |
| ROE Average | 10% | 10% | 15% | 13% |
| ROCE Average | 13% | 14% | 19% | 17% |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 203 | 197 | 312 | 388 | 570 | 751 | 801 | 918 | 971 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14 | 13 |
| Borrowings | 27 | 27 | 1 | 1 | 0 | 3 | 8 | 0 | 0 |
| Other Non-Current Liabilities | 27 | 33 | 17 | 7 | 6 | 58 | 51 | 72 | 68 |
| Total Current Liabilities | 115 | 83 | 144 | 184 | 302 | 273 | 117 | 121 | 147 |
| Total Liabilities | 372 | 340 | 473 | 579 | 878 | 1085 | 977 | 1126 | 1199 |
| Fixed Assets | 195 | 187 | 161 | 110 | 130 | 102 | 120 | 127 | 87 |
| Other Non-Current Assets | 59 | 38 | 36 | 89 | 170 | 289 | 265 | 361 | 368 |
| Total Current Assets | 119 | 115 | 276 | 380 | 579 | 694 | 592 | 638 | 742 |
| Total Assets | 372 | 340 | 473 | 579 | 878 | 1085 | 977 | 1126 | 1199 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 6 | 6 | 2 | 42 | 7 | 214 | 226 | 329 | 369 |
| Cash Flow from Operating Activities | 21 | -8 | 99 | 71 | 60 | 141 | 140 | 65 | 39 |
| Cash Flow from Investing Activities | -9 | -1 | -38 | -115 | -1 | -112 | -20 | -8 | 37 |
| Cash Flow from Financing Activities | -12 | 11 | -22 | 10 | -51 | -17 | -17 | -18 | -11 |
| Net Cash Inflow / Outflow | -0 | 2 | 40 | -35 | 7 | 13 | 103 | 40 | 65 |
| Closing Cash & Cash Equivalent | 6 | 8 | 42 | 7 | 14 | 226 | 329 | 369 | 434 |
| # | Mar 2016 | Mar 2017 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 17.02 | 5.93 | 22.08 | 35.29 | 59.88 | 89.87 | 46.06 | 52.47 | 53.25 |
| CEPS(Rs) | 19.3 | 12.97 | 51.37 | 64.77 | 71.08 | 101.14 | 52.18 | 55.22 | 56.76 |
| DPS(Rs) | 1.5 | 1.5 | 2.5 | 3 | 3.5 | 4 | 3 | 3 | 3 |
| Book NAV/Share(Rs) | 138.27 | 133.52 | 181.51 | 226.03 | 332.24 | 437.48 | 466.43 | 534.98 | 565.76 |
| Core EBITDA Margin(%) | 11.6 | 12.97 | 14.8 | 14.31 | 11.73 | 10.9 | 12.76 | 14.39 | 13.23 |
| EBIT Margin(%) | 9.63 | 7.04 | 8.07 | 9.48 | 11.06 | 11.82 | 12.84 | 18.98 | 18.32 |
| Pre Tax Margin(%) | 6.68 | 5.13 | 6.59 | 8.88 | 10.81 | 11.53 | 12.38 | 18.67 | 18.07 |
| PAT Margin (%) | 4.9 | 5.19 | 5.5 | 6.65 | 8.11 | 9.34 | 9.11 | 13.71 | 13.49 |
| Cash Profit Margin (%) | 7.45 | 11.34 | 12.8 | 12.21 | 9.62 | 10.51 | 10.33 | 14.86 | 14.57 |
| ROA(%) | 5.02 | 2.45 | 9.32 | 11.51 | 14.11 | 15.71 | 7.66 | 8.32 | 7.76 |
| ROE(%) | 9.18 | 4.37 | 14.92 | 17.32 | 21.45 | 23.35 | 10.18 | 10.18 | 9.55 |
| ROCE(%) | 12.72 | 4.2 | 17.58 | 21.41 | 26.99 | 28.87 | 14.16 | 14.02 | 12.96 |
| Receivable days | 51.13 | 114.83 | 35.63 | 35.79 | 32.92 | 31.06 | 53.86 | 60.11 | 51.13 |
| Inventory Days | 21.22 | 37.22 | 12.94 | 15.31 | 26.44 | 29.82 | 33.15 | 20.43 | 24.52 |
| Payable days | 33.59 | 51.41 | 13.98 | 12.36 | 19.18 | 23.23 | 32.02 | 17.37 | 14.39 |
| PER(x) | 3.94 | 20.81 | 3.27 | 6.7 | 7.91 | 4.58 | 10.68 | 9.38 | 7.22 |
| Price/Book(x) | 0.48 | 0.92 | 0.4 | 1.05 | 1.43 | 0.94 | 1.05 | 0.92 | 0.68 |
| Dividend Yield(%) | 2.24 | 1.21 | 3.46 | 1.27 | 0.74 | 0.97 | 0.61 | 0.61 | 0.78 |
| EV/Net Sales(x) | 0.49 | 1.54 | 0.12 | 0.36 | 0.57 | 0.3 | 0.6 | 0.74 | 0.33 |
| EV/Core EBITDA(x) | 3.72 | 11.41 | 0.78 | 2.4 | 4.51 | 2.28 | 3.9 | 3.6 | 1.55 |
| Net Sales Growth(%) | 0 | -54.8 | 319.45 | 32.18 | 39.13 | 30.21 | -47.52 | -26.35 | 4.57 |
| EBIT Growth(%) | 0 | -67.73 | 369.42 | 55.22 | 62.41 | 39.22 | -42.99 | 8.87 | 1.15 |
| PAT Growth(%) | 0 | -53.26 | 334.04 | 59.79 | 69.68 | 50.08 | -48.81 | 10.76 | 3.11 |
| EPS Growth(%) | 0 | -65.14 | 272.13 | 59.79 | 69.68 | 50.08 | -48.75 | 13.93 | 1.47 |
| Debt/Equity(x) | 0.42 | 0.4 | 0.15 | 0.16 | 0.03 | 0.02 | 0.01 | 0 | 0 |
| Current Ratio(x) | 1.03 | 1.38 | 1.92 | 2.07 | 1.92 | 2.54 | 5.06 | 5.27 | 5.06 |
| Quick Ratio(x) | 0.84 | 1.23 | 1.67 | 1.85 | 1.44 | 2.08 | 4.79 | 4.94 | 4.72 |
| Interest Cover(x) | 3.27 | 3.7 | 5.47 | 15.76 | 43.7 | 41.09 | 27.92 | 61.21 | 73.02 |
| Total Debt/Mcap(x) | 0.86 | 0.41 | 0.37 | 0.15 | 0.02 | 0.02 | 0.01 | 0 | 0 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 61.84 | 61.84 | 61.84 | 61.84 | 61.84 | 61.84 | 61.84 | 61.84 | 61.84 | 62.19 |
| FII | 0.56 | 0.14 | 0.08 | 0.14 | 0.12 | 0.06 | 0.06 | 0.06 | 0.06 | 0.3 |
| DII | 0.03 | 0.03 | 0.03 | 0.04 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
| Public | 37.57 | 37.98 | 38.05 | 37.98 | 38 | 38.05 | 38.05 | 38.05 | 38.05 | 37.47 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 1.06 | 1.06 | 1.06 | 1.06 | 1.06 | 1.06 | 1.06 | 1.06 | 1.06 | 1.07 |
| FII | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.64 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.64 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1.72 | 1.72 | 1.72 | 1.72 | 1.72 | 1.72 | 1.72 | 1.72 | 1.72 | 1.72 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +5% | -26% | -6% | — |
| Operating Profit CAGR | +8% | -13% | +1% | — |
| PAT CAGR | +3% | -16% | +8% | — |
| Share Price CAGR | -12% | -5% | +8% | +14% |
| ROE Average | +10% | +10% | +15% | +13% |
| ROCE Average | +13% | +14% | +19% | +17% |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 61.84 | 61.84 | 61.84 | 61.84 | 61.84 | 61.84 | 61.84 | 61.84 | 61.84 | 62.19 |
| FII | 0.56 | 0.14 | 0.08 | 0.14 | 0.12 | 0.06 | 0.06 | 0.06 | 0.06 | 0.3 |
| DII | 0.03 | 0.03 | 0.03 | 0.04 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
| Public | 37.57 | 37.98 | 38.05 | 37.98 | 38 | 38.05 | 38.05 | 38.05 | 38.05 | 37.47 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 1.06 | 1.06 | 1.06 | 1.06 | 1.06 | 1.06 | 1.06 | 1.06 | 1.06 | 1.07 |
| FII | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.64 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.64 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1.72 | 1.72 | 1.72 | 1.72 | 1.72 | 1.72 | 1.72 | 1.72 | 1.72 | 1.72 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.